William Blair Issues Positive Forecast for Amedisys Earnings

Key Points

• William Blair has raised its Q3 2025 earnings estimate for Amedisys from $1.05 to $1.11 per share, with a full-year earnings estimate of $4.40 per share.
• Shares of Amedisys opened at $98.69 with a market capitalization of $3.24 billion and a price-to-earnings ratio of 38.40, reflecting strong investor interest.
• Amedisys reported Q2 2025 earnings of $1.54 EPS, which exceeded the consensus estimate of $1.39, along with a revenue of $621.86 million.

Amedisys, Inc. (NASDAQ:AMED - Free Report) - William Blair raised their Q3 2025 earnings estimates for shares of Amedisys in a research report issued to clients and investors on Tuesday, July 29th. William Blair analyst M. Larew now forecasts that the health services provider will earn $1.11 per share for the quarter, up from their prior estimate of $1.05. The consensus estimate for Amedisys' current full-year earnings is $4.40 per share. William Blair also issued estimates for Amedisys' Q4 2025 earnings at $1.19 EPS, FY2025 earnings at $5.09 EPS, Q2 2026 earnings at $1.38 EPS, Q3 2026 earnings at $1.25 EPS, Q4 2026 earnings at $1.24 EPS and FY2026 earnings at $4.78 EPS.

Other analysts also recently issued research reports about the stock. Wall Street Zen downgraded shares of Amedisys from a "strong-buy" rating to a "buy" rating in a research report on Saturday, May 24th. Royal Bank Of Canada reiterated an "outperform" rating and issued a $100.00 target price on shares of Amedisys in a report on Wednesday, April 16th.

Amedisys Trading Down 0.1%

Shares of AMED stock traded down $0.09 during trading hours on Thursday, hitting $98.51. 872,139 shares of the company were exchanged, compared to its average volume of 370,725. The firm has a market cap of $3.24 billion, a P/E ratio of 38.33, a P/E/G ratio of 1.33 and a beta of 0.89. Amedisys has a fifty-two week low of $82.15 and a fifty-two week high of $99.00. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.29 and a current ratio of 1.36. The company has a 50 day simple moving average of $96.75 and a two-hundred day simple moving average of $94.17.

Amedisys (NASDAQ:AMED - Get Free Report) last announced its quarterly earnings data on Tuesday, July 29th. The health services provider reported $1.54 EPS for the quarter, topping the consensus estimate of $1.39 by $0.15. The company had revenue of $621.86 million during the quarter, compared to the consensus estimate of $614.61 million. Amedisys had a net margin of 3.56% and a return on equity of 12.91%. The company's quarterly revenue was up 5.2% on a year-over-year basis. During the same quarter last year, the firm posted $0.98 EPS.

Institutional Trading of Amedisys

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Hexagon Capital Partners LLC boosted its position in shares of Amedisys by 108.1% during the first quarter. Hexagon Capital Partners LLC now owns 310 shares of the health services provider's stock valued at $29,000 after buying an additional 161 shares during the last quarter. MassMutual Private Wealth & Trust FSB lifted its stake in Amedisys by 56.1% during the 1st quarter. MassMutual Private Wealth & Trust FSB now owns 334 shares of the health services provider's stock valued at $31,000 after acquiring an additional 120 shares in the last quarter. Fifth Third Bancorp lifted its stake in Amedisys by 68.1% during the 1st quarter. Fifth Third Bancorp now owns 348 shares of the health services provider's stock valued at $32,000 after acquiring an additional 141 shares in the last quarter. Caitong International Asset Management Co. Ltd bought a new position in Amedisys during the 2nd quarter valued at $32,000. Finally, UMB Bank n.a. lifted its stake in Amedisys by 100.0% during the 1st quarter. UMB Bank n.a. now owns 386 shares of the health services provider's stock valued at $36,000 after acquiring an additional 193 shares in the last quarter. 94.36% of the stock is owned by institutional investors.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.